Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...

Patent expirations from Brukinsa’s existing competitors may bring biosimilar drugs into the field before Brukinsa reaches its full commercial potential. BeiGene may lose the lawsuit to AbbVie over ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

As a leading provider of direct-to-patient and direct-to-physician marketing solutions, Health Monitor Network is once again expanding its senior leadership team during this period of strong growth.

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

This acquisition will allow AbbVie to enter the commercial ovarian cancer market. Despite these strategic acquisitions, ...

Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

Barclays analyst Carter Gould keeps an Overweight rating on AbbVie (ABBV) after the company disclosed that both of its registrational studies ...